Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
Date:4/30/2008

>

the enhancement of the apoptotic effect when added to either

vincristine or fludarabine. The other poster reported that in vivo

immunostimulatory responses to ANA773 can be effectively modified by

varying the schedule of dose administration, including every other day

dosing (QOD), and three consecutive days of dosing within each seven

day cycle (3-on, 4-off).

Program Updates and Revised Cash Outlook for 2008

-- ANA598 Development Activities. Based on promising results from the

preclinical evaluation of ANA598, Anadys has made the strategic

decision to accelerate certain non-clinical activities for this

program, including further manufacturing of drug substance and

conducting additional toxicology studies. These studies include a

combination toxicology study with ribavirin that will support the

clinical investigation of ANA598 in combination with interferon and

ribavirin, as well as studies extending the duration of dosing beyond

the recently completed 28 day toxicology study. If ANA598 is

successful in early stage clinical trials, it is anticipated that the

acceleration of these non-clinical activities into 2008 will enable a

more rapid and continuous development path into mid-stage clinical

trials during 2009.

-- ANA773 Development Activities. Anadys continues to explore the safety

and tolerability profile of ANA773 in the ongoing Phase I trial and

expects to identify pharmacologically active doses and establish the

profile of immune stimulation this year, which information will support

the future design of clinical trials of ANA773 (alone or in

combinations) in specific tumor types. While Anadys expects the rate

of enrollment in the ANA773 oncology trial to increase in the coming

quarters, the Company now expects the pac
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
2. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
3. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
4. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
5. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
6. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
9. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
10. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
11. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Cynvenio, a cancer ... through the genomic analysis of tumor cells in the ... a web-based cancer decision support application powered by CollabRx, ... Cynvenio’s ClearID™ genomic test, Therapy Finder will provide breast ...
(Date:1/15/2014)... 15, 2014 More than 5 million ... 1 in 3 seniors will die with Alzheimer’s or ... jaw-dropping figures have shocked many Americans into looking for ... prevent these tragic age-related cognitive disorders. Jonathan Weisman, president ...
(Date:1/15/2014)... 2014 Freeslate, Inc ., the ... that Lupin Limited, one of India’s top five pharmaceutical ... PharmD System for high throughput solid form screening. ... on a wide range of quality, affordable generic and ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... University of Wisconsin-Madison researchers led by stem-cell pioneer ... cultures under cleaner and better-defined lab conditions than ... journal Nature Biotechnology, could pave the way for ... because of animal-cell contamination. Growing stem cells in ...
... continues to make stem-cell advances , such as ... things aren't going so well elsewhere in the world: ... South Korean stem-cell researcher, fell from grace in just ... stem-cell research results. , ,Originally, the allegations against him ...
... the original story was based on an official summary that referred ... certain amendments. Under the law as enacted, the source code would ... analyzed in the case of a recount, but not open to ... it may have caused. , , Madison, Wis. ...
Cached Biology Technology:Stem-cell controversies slow progress 2Voting machine source code must be available for review 2
(Date:7/10/2014)... chronic inflammatory skin diseases psoriasis* and eczema** are similar ... to base their decision on which treatment should be ... tissue samples. A team of researchers at the Helmholtz ... have now analyzed the molecular processes that occur in ... them for the first time to gain a detailed ...
(Date:7/10/2014)... July 10, 2014Women in the West African nation ... family planning option. Sayana Press has the potential ... of the health system and in communities by ... contraceptivePfizer,s Depo-Provera (depot medroxyprogesterone acetate)with the BD Uniject ... of four African countries expected to begin introducing ...
(Date:7/9/2014)... that,s not why the Millennials are eating it, according to ... annual International Recognition Days convention July 10th in Milwaukee. , ... that are quick, easy to cook and that can help ... about any health benefits of Tofu," said lead Cornell researcher ... it,s quick to cook and it,s filling.", The study of ...
Breaking Biology News(10 mins):New diagnostic test to distinguish psoriasis from eczema 2Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 2Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 3
... LA JOLLA, Calif., September 25 2013 A new ... called medulloblastoma has been developed by researchers at Sanford-Burnham ... cellsthe cells that are critical for maintaining tumor growthand ... are essential for tumor progression. The process destroys the ...
... how their meat is sourced, with animal welfare ... many purchases. Unfortunately, many widely-used livestock production methods ... from the University of Cambridge has identified what ... silvopastoral systems which include shrubs and trees with ...
... , Sept. 25, 2013   GenoVive , an innovator ... against the emerging "globesity" epidemic through its development of ... on each individual,s unique metabolism.  "Weight Loss Designed by ... to customize an all natural meal and exercise program ...
Cached Biology News:New approach to treating human brain cancer could lead to improved outcomes 2New approach to treating human brain cancer could lead to improved outcomes 3Sustainable livestock production is possible 2Sustainable livestock production is possible 3"GenoVive is changing the face of personalized health by continuing research efforts with Harvard." 2
Human Ig Lambda-chain, clone ICO-16, Monoclonal Antibody...
Phospho-FADD (Ser194) Antibody (Human Specific)...
HSD17B3 Immunogen: HSD17B3 (NP_000188, 29 a.a. ~ 120 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Phospho-mu-Opioid Receptor (Ser375) Antibody...
Biology Products: